Study of Ritlecitinib for Chronic Hives Not Helped by Antihistamines
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study is testing an experimental daily pill called ritlecitinib for adults whose chronic hives don’t go away with standard antihistamines. It may be a new option if your hives are active and you are not on omalizumab or are willing to stop it for several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had chronic spontaneous urticaria (unexplained hives that come and go) for at least 3 months.
- Your hives are still bothering you even after taking prescription antihistamines (like Zyrtec, Claritin, or Allegra) every day.
- You are willing to be off omalizumab (Xolair) for at least 4 months if you have used it before.
- You do not have other skin conditions that cause hives or itching (like vasculitis or atopic dermatitis).
- You have not had a recent or serious infection (like TB, shingles, hepatitis, or HIV) or are currently on strong antibiotics.
- You are over 18 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called HRS-3095 to see if it can help people whose chronic hives (itchy welts) do not get better with standard allergy pills. It aims to reduce itching and wheals and improve quality of life.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This study tests a new investigational drug called AK139 to see if it can reduce the itching and hives caused by chronic spontaneous urticaria (also known as chronic hives). It may offer a new treatment option for people whose hives are not well controlled with antihistamines.
This study tests an experimental capsule (HS-10561) to see if it is safe and works for people with chronic spontaneous urticaria, which causes hives and itching without a clear trigger. If you have had hives for at least 6 months, you might be able to join.
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.